Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19

J Antimicrob Chemother. 2023 Feb 1;78(2):555-558. doi: 10.1093/jac/dkac433.

Lucia Graziani¹, Leonardo Gori¹, Tommaso Manciulli¹, Gregorio Basile¹, Irene Campolmi², Beatrice Borchi², Marta di Dio³, Marta Mattei¹, Greta Ciurleo¹, Maria Ciliberti³, Francesca Malentacchi⁴, Marco Coppi¹, Alessandro Morettini³, Paola Parronchi^{1

5}, Gian Maria Rossolini^{1

4}, Alessandro Bartoloni^{1

2}, Sara Tomassetti^{1

6}, Michele Spinicci^{1

2}

¹ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
² Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
³ Internal Medicine Unit 2, Careggi University Hospital, Florence, Italy.
⁴ Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy.
⁵ Immunology and Cell Therapy Unit, Careggi University Hospital, Florence, Italy.
⁶ Interventional Pneumology Unit, Careggi University Hospital, Florence, Italy.

No abstract available

Publication types